Home > Our Company > Board of Directors
Dr. Guoqing Jiang, MD - Chairman & CEO
Dr. Jiang is a charismatic, natural leader and well-respected industry veteran with over 15 years of extensive experience and a proven track record. Prior to Tianyin, Dr. Jiang served senior management positions at several pharmaceutical companies including a post as the CEO at Kelun Pharmaceutical Group and helped build the company from inception to become currently the world's largest producer of intravenous solution products and one of China's leading distributor of pharmaceutical and traditional Chinese medicine products. Dr. Jiang was once a lecturer and resident physician for over 5 years after graduating as a Medical Doctor from Jiangsu University Medical School.
Dr. Jiang is a charismatic, natural leader and well-respected industry veteran with over 15 years of extensive experience and a proven track record. Prior to Tianyin, Dr. Jiang served senior management positions at several pharmaceutical companies including a post as the CEO at Kelun Pharmaceutical Group and helped build the company from inception to become currently the world's largest producer of intravenous solution products and one of China's leading distributor of pharmaceutical and traditional Chinese medicine products. Dr. Jiang was once a lecturer and resident physician for over 5 years after graduating as a Medical Doctor from Jiangsu University Medical School.
Dr. James Jiayuan Tong, M.D. Ph.D., Chief Financial Officer, Chief Business & Development Officer
Dr. Tong joined Tianyin as CFO and CBDO, and a member of the Company's Board of Directors on April 1, 2010. Prior to his position at Tianyin, Dr. Tong was the Head of China Healthcare Investment Banking at ROTH Capital Partners, Newport Beach, CA. He initially joined ROTH as an equity research analyst, in charge of China healthcare research universe, covering a series of U.S.-listed Chinese pharmaceutical, biotech, medical devices and drug retail businesses. Prior to that, Dr. Tong was a biotechnology analyst at Rodman & Renshaw, New York, covering biotech entities focusing on molecular diagnostics and cures for Alzheimer's disease, multiple sclerosis and cancer. Before his Wall Street career, Dr. Tong was Principal Investigator at Marine Biological Laboratory (MBL) sponsored by Grass Foundation at Woods Hole, MA and a Senior Research Fellow at University of California, Irvine (UCI). Dr. Tong was awarded Ph.D. in Neurobiology and Behavior from Cold Spring Harbor Laboratory / Stony Brook University Neuroscience program. He developed an innovative method to significantly extend life spans of animals based on his work on mitochondria, aging and learning disorders in Neurofibromatosis-1 (NF1) disease. He published three first-authored Nature articles and currently holds two patents. Dr. Tong received his medical degree from Peking University Health Science Center.
Dr. Tong joined Tianyin as CFO and CBDO, and a member of the Company's Board of Directors on April 1, 2010. Prior to his position at Tianyin, Dr. Tong was the Head of China Healthcare Investment Banking at ROTH Capital Partners, Newport Beach, CA. He initially joined ROTH as an equity research analyst, in charge of China healthcare research universe, covering a series of U.S.-listed Chinese pharmaceutical, biotech, medical devices and drug retail businesses. Prior to that, Dr. Tong was a biotechnology analyst at Rodman & Renshaw, New York, covering biotech entities focusing on molecular diagnostics and cures for Alzheimer's disease, multiple sclerosis and cancer. Before his Wall Street career, Dr. Tong was Principal Investigator at Marine Biological Laboratory (MBL) sponsored by Grass Foundation at Woods Hole, MA and a Senior Research Fellow at University of California, Irvine (UCI). Dr. Tong was awarded Ph.D. in Neurobiology and Behavior from Cold Spring Harbor Laboratory / Stony Brook University Neuroscience program. He developed an innovative method to significantly extend life spans of animals based on his work on mitochondria, aging and learning disorders in Neurofibromatosis-1 (NF1) disease. He published three first-authored Nature articles and currently holds two patents. Dr. Tong received his medical degree from Peking University Health Science Center.
Professor Zhang Zunjian, Ph.D. - Independent Board Director
Professor Zhang is currently Executive Director at the Center for Instrument Analysis and the Deputy Director of the School of Pharmacy at China Pharmaceutical University. His responsibility also includes the Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education at the university. He is a member of the Chinese Pharmacopoeia Commission, a price evaluation expert of the State Commission of Development and Reform and a SFDA expert review committee member for new drugs and health food products. Professor Zhang is Deputy Executive Director at the Analytical Division of the Jiangsu Provincial Society of Chemistry and Chemical Engineering. He also serves as an editor for Journal of China Pharmaceutical University and Journal of Chinese Traditional and Herbal Drugs etc. Professor Zhang is mainly engaged in the in vitro and in vivo quality evaluation of pharmaceuticals, specializing on the efficacy of in vivo pharmaceuticals and the chromatography / spectrometry / mass spectrometry analysis of the TCM active ingredients. Professor Zhang has been the lead investigator of more than 10 national research projects: the major scientific project "Innovative Researches of Major New Medicines" during the Eleventh Five-year plan – focusing on the drug quality control techniques of the large integrated pharmaceuticals discovery platform, major national scientific projects of the Tenth Five-year, the National Natural Science Foundation of China, the specific scientific research projects of the State Administration of Traditional Chinese Medicine Medical, the Natural Science Foundation of Jiangsu Province and the high-level personnel funding projects on the provincial level. He has also been the principle investigator of more than 100 registered categories of Chinese and Western new medicines for the quality control, fingerprinting, process analysis and quality evaluation, preclinical and clinical pharmacokinetic studies. Dr. Zhang has published more than 150 peer-reviewed research papers in well recognized journals worldwide, more than 70 of which were SCI papers.
Professor Zhang is currently Executive Director at the Center for Instrument Analysis and the Deputy Director of the School of Pharmacy at China Pharmaceutical University. His responsibility also includes the Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education at the university. He is a member of the Chinese Pharmacopoeia Commission, a price evaluation expert of the State Commission of Development and Reform and a SFDA expert review committee member for new drugs and health food products. Professor Zhang is Deputy Executive Director at the Analytical Division of the Jiangsu Provincial Society of Chemistry and Chemical Engineering. He also serves as an editor for Journal of China Pharmaceutical University and Journal of Chinese Traditional and Herbal Drugs etc. Professor Zhang is mainly engaged in the in vitro and in vivo quality evaluation of pharmaceuticals, specializing on the efficacy of in vivo pharmaceuticals and the chromatography / spectrometry / mass spectrometry analysis of the TCM active ingredients. Professor Zhang has been the lead investigator of more than 10 national research projects: the major scientific project "Innovative Researches of Major New Medicines" during the Eleventh Five-year plan – focusing on the drug quality control techniques of the large integrated pharmaceuticals discovery platform, major national scientific projects of the Tenth Five-year, the National Natural Science Foundation of China, the specific scientific research projects of the State Administration of Traditional Chinese Medicine Medical, the Natural Science Foundation of Jiangsu Province and the high-level personnel funding projects on the provincial level. He has also been the principle investigator of more than 100 registered categories of Chinese and Western new medicines for the quality control, fingerprinting, process analysis and quality evaluation, preclinical and clinical pharmacokinetic studies. Dr. Zhang has published more than 150 peer-reviewed research papers in well recognized journals worldwide, more than 70 of which were SCI papers.
Professor Jianping Hou, Ph.D. - Independent Board Director
Professor Hou is currently a graduate school faculty advisor at Shaanxi University of Traditional Chinese Medicine. He has published over dozens of peer-reviewed research papers and participated in the compiling and editing of a number of college textbooks in traditional Chinese medicine. Professor Hou is a principal investigator in more than 10 national research projects and has received the scientific achievement award from the State Administration of Traditional Chinese Medicine. He is a SFDA expert review committee member for new drugs and health food products. He is also an expert review panel member for new drugs and side effects at SFDA Shaanxi Province. Professor Hou is Executive Director at Shaanxi Pharmacological Society and the Clinical Pharmacology Committee of Shaanxi Pharmaceutical Association. Professor Hou has once served various senior management positions at Sizhuang Research Institute of Nutriceutics, Xikang Pharmaceutical Co., Ltd. and Sizhuang Pharmaceutical Co., Ltd. He received his Bachelor of Pharmacy and Master's degree in Pharmacology of Traditional Chinese Medicine from Shaanxi University of Traditional Chinese Medicine. He earned his Ph.D. degree in Pharmacology of Traditional Chinese Medicine from Beijing University. Professor Hou also completed an EMBA training program for top pharmaceutical executives at Beijing University.
Professor Hou is currently a graduate school faculty advisor at Shaanxi University of Traditional Chinese Medicine. He has published over dozens of peer-reviewed research papers and participated in the compiling and editing of a number of college textbooks in traditional Chinese medicine. Professor Hou is a principal investigator in more than 10 national research projects and has received the scientific achievement award from the State Administration of Traditional Chinese Medicine. He is a SFDA expert review committee member for new drugs and health food products. He is also an expert review panel member for new drugs and side effects at SFDA Shaanxi Province. Professor Hou is Executive Director at Shaanxi Pharmacological Society and the Clinical Pharmacology Committee of Shaanxi Pharmaceutical Association. Professor Hou has once served various senior management positions at Sizhuang Research Institute of Nutriceutics, Xikang Pharmaceutical Co., Ltd. and Sizhuang Pharmaceutical Co., Ltd. He received his Bachelor of Pharmacy and Master's degree in Pharmacology of Traditional Chinese Medicine from Shaanxi University of Traditional Chinese Medicine. He earned his Ph.D. degree in Pharmacology of Traditional Chinese Medicine from Beijing University. Professor Hou also completed an EMBA training program for top pharmaceutical executives at Beijing University.
Mr. James T. McCubbin - Independent Board Director
Mr. McCubbin currently serves as a Director, Vice President and Chief Financial Officer at WidePoint Corporation, an American Stock Exchange listed company (AMEX: WYY). Prior to the commencement of his employment with WidePoint, he held various senior financial management positions with several companies in the financial and government sectors. Mr. McCubbin is a director and chairman of the audit committee for Red Mile Entertainment, Inc., a developer and publisher of interactive entertainment software. Mr. McCubbin is a graduate of the University of Maryland with a Bachelor of Science Degree in Finance and a Master's Degree in International Management.
Mr. McCubbin currently serves as a Director, Vice President and Chief Financial Officer at WidePoint Corporation, an American Stock Exchange listed company (AMEX: WYY). Prior to the commencement of his employment with WidePoint, he held various senior financial management positions with several companies in the financial and government sectors. Mr. McCubbin is a director and chairman of the audit committee for Red Mile Entertainment, Inc., a developer and publisher of interactive entertainment software. Mr. McCubbin is a graduate of the University of Maryland with a Bachelor of Science Degree in Finance and a Master's Degree in International Management.
